These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38303259)

  • 1. [Clinical Outcomes of Treatment for Esophageal Cancer Recurrence after Surgery].
    Takebayashi K; Kaida S; Otake R; Matsunaga T; Miyake T; Kojima M; Tani S; Maehira H; Mori H; Nishina Y; Zen Y; Takenaka Y; Naito S; Ishikawa H; Tani M
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1944-1946. PubMed ID: 38303259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How does presurgical chemotherapy influence the efficiency of treatment for esophageal cancer recurrence after curative esophagectomy?
    Taniyama Y; Sakurai T; Hikage M; Okamoto H; Sato C; Takaya K; Unno M; Kamei T
    Thorac Cancer; 2019 Apr; 10(4):769-774. PubMed ID: 30756477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival outcomes of consolidation chemoradiotherapy in esophageal cancer patients who achieve clinical complete response but refuse surgery after neoadjuvant chemoradiotherapy.
    Fang HY; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27878893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
    Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
    World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of neoadjuvant chemotherapy followed by surgery versus definitive chemoradiotherapy with proton beam for locally advanced esophageal squamous cell carcinoma.
    Ogawa K; Ishikawa H; Hisakura K; Hiroshima Y; Moriwaki T; Yamada T; Yamamoto Y; Akashi Y; Owada Y; Ohara Y; Enomoto T; Furuya K; Doi M; Shimomura O; Takahashi K; Hashimoto S; Sakurai H; Oda T
    Int J Clin Oncol; 2021 Oct; 26(10):1856-1863. PubMed ID: 34241725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
    BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes.
    Xi M; Yang Y; Zhang L; Yang H; Merrell KW; Hallemeier CL; Shen RK; Haddock MG; Hofstetter WL; Maru DM; Ho L; Wu CC; Liu M; Lin SH
    Ann Surg; 2019 Apr; 269(4):663-670. PubMed ID: 29334555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategies in recurrent esophageal or junctional cancer.
    Butter R; Lagarde SM; van Oijen MGH; Anderegg MCJ; Gisbertz SS; Meijer SL; Hulshof MCCM; Bergman JJGHM; van Berge Henegouwen MI; van Laarhoven HWM
    Dis Esophagus; 2017 Sep; 30(9):1-9. PubMed ID: 28859371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
    Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma.
    Lv J; Cao XF; Zhu B; Ji L; Tao L; Wang DD
    World J Gastroenterol; 2009 Oct; 15(39):4962-8. PubMed ID: 19842230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
    Chao YK; Tseng CK; Wen YW; Liu YH; Wan YL; Chiu CT; Chang WC; Chang HK
    Ann Surg Oncol; 2013 Sep; 20(9):3000-8. PubMed ID: 23584515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer.
    Yoshii T; Ohkawa S; Tamai S; Kameda Y
    Dis Esophagus; 2013 Jul; 26(5):496-502. PubMed ID: 22676622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer.
    Hattori S; Muto M; Ohtsu A; Boku N; Manabe T; Doi T; Ishikura S; Yoshida S
    Gastrointest Endosc; 2003 Jul; 58(1):65-70. PubMed ID: 12838223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer.
    Makazu M; Kato K; Takisawa H; Yoshinaga S; Oda I; Saito Y; Mayahara H; Ito Y; Itami J; Hamaguchi T; Yamada Y; Shimada Y
    Dis Esophagus; 2014 Jan; 27(1):42-9. PubMed ID: 23442160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road.
    Depypere L; Lerut T; Moons J; Coosemans W; Decker G; Van Veer H; De Leyn P; Nafteux P
    Dis Esophagus; 2017 Jan; 30(1):1-8. PubMed ID: 27704661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.
    Matsuda S; Takeuchi H; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Dis Esophagus; 2014; 27(7):654-61. PubMed ID: 23980622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma.
    Zhou N; Mitchell KG; Corsini EM; Truong VTT; Antonoff MB; Mehran RJ; Rajaram R; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Ajani JA; Hofstetter WL
    Br J Surg; 2021 Oct; 108(10):1207-1215. PubMed ID: 34095952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer.
    Urschel JD; Vasan H; Blewett CJ
    Am J Surg; 2002 Mar; 183(3):274-9. PubMed ID: 11943125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.